{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:17:02Z","timestamp":1788963422129,"version":"build-2803163510"},"reference-count":42,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Xiangya Hospital Partnership Support with Hunan University of Medicine General Hospital for Clinical Research and Cohort Development","award":["XYDL-ZR02"],"award-info":[{"award-number":["XYDL-ZR02"]}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2021JJ30923"],"award-info":[{"award-number":["2021JJ30923"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2023JJ60144"],"award-info":[{"award-number":["2023JJ60144"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Provincial Science and Technology Innovation Leading Talents Project of Hunan Province","award":["2021RC4014"],"award-info":[{"award-number":["2021RC4014"]}]},{"name":"Central South University Research Programme of Advanced Interdisciplinary Studies","award":["2023QYJC011"],"award-info":[{"award-number":["2023QYJC011"]}]},{"name":"The Scientific Research Program of FuRong Laboratory","award":["\uff08No.2025PT5001\uff09"],"award-info":[{"award-number":["\uff08No.2025PT5001\uff09"]}]},{"name":"Major Science and Technology Projects in Changsha, China","award":["kq2301008"],"award-info":[{"award-number":["kq2301008"]}]},{"name":"CSPC NBP Pharmaceutical Co., Ltd"},{"name":"National Science & Technology Fundamental Resources Investigation Program of China","award":["2018FY100900"],"award-info":[{"award-number":["2018FY100900"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471364"],"award-info":[{"award-number":["82471364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Health High-Level Talent Scientific Research Project","award":["R2023069"],"award-info":[{"award-number":["R2023069"]}]},{"name":"Major Basic Research Projects in Hunan Province","award":["2024JC0004"],"award-info":[{"award-number":["2024JC0004"]}]},{"name":"Key Science and Technology Innovation Project of Jiangxi Provincial Health Commission","award":["2025ZD003"],"award-info":[{"award-number":["2025ZD003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intravenous thrombolysis is the standard early treatment for acute ischaemic stroke (AIS), yet a substantial proportion of patients, particularly those with mild disabling deficits, do not achieve favourable functional recovery. Tenecteplase (TNK), a fibrin-specific thrombolytic agent administered as a single bolus, and butylphthalide (NBP), a multi-mechanism neuroprotective agent, have each shown benefit in AIS. However, whether their combination confers additional benefit in mild disabling AIS remains unknown. This trial aims to determine whether adding NBP to TNK improves functional outcomes in patients with mild disabling ischaemic stroke treated within 4.5 hours of symptom onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>BENEFIT-2 is a prospective, multicentre, randomised, double-blind, active-controlled trial. Eligible patients will be randomised 1:1 to receive either TNK plus NBP (combination group) or TNK plus placebo (control group) via block randomisation. The intervention comprises intravenous NBP 25\u2009mg\/100\u2009mL two times per day for 7\u2009days, followed by oral NBP 0.2\u2009g three times per day up to day 14, with matching placebos for the control group. Key eligibility criteria include age 18\u201380 years, symptom onset within 4.5\u2009hours, baseline National Institutes of Health Stroke Scale (NIHSS) score 2\u20135 with persistent unilateral weakness or speech impairment, and prestroke modified Rankin Scale (mRS) score 0 or 1. The primary outcome is the proportion of patients achieving mRS 0\u20131 at 90 days (allowable window \u00b17\u2009days). Secondary endpoints include change in NIHSS, stroke recurrence, major vascular events, quality of life measured by EQ-5D and penumbral salvage on imaging. Safety endpoints comprise symptomatic intracranial haemorrhage, vascular death, all-cause mortality and other adverse events within 90 days. The primary analysis will follow the intention-to-treat principle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval has been obtained from the Independent Ethics Committee of Xiangya Hospital (No. 2026020399), Central South University. Results will be published in peer-reviewed journals and presented at academic conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial \" xlink:href=\"NCT07369999\">NCT07369999<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-119290","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:57:56Z","timestamp":1788962276000},"page":"e119290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Butylphthalide combined with tenecteplase in mild disabling acute ischaemic stroke in China (BENEFIT-2): study protocol for a multicentre, randomised, double-blind, active-controlled trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07369999","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07369999","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qiaoling","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[{"name":"Vascular Neurology, HonorHealth \/ ASU School of Medicine & Advanced Medical Engineering, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-2464","authenticated-orcid":false,"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1449-1339","authenticated-orcid":false,"given":"Xiangbin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-9303","authenticated-orcid":false,"given":"Minxue","family":"Shen","sequence":"additional","affiliation":[{"name":"Dermatology, Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-432X","authenticated-orcid":false,"given":"Le","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Changsha, Hunan, China"},{"name":"Brain Health Center of Hunan Province, Changsha, Hunan, China"},{"name":"Human Brain Disease Biological Resources Platform of Hunan Province, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026090805001769000_16.9.e119290.1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30500-3"},{"key":"2026090805001769000_16.9.e119290.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00369-7"},{"key":"2026090805001769000_16.9.e119290.3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.593897"},{"key":"2026090805001769000_16.9.e119290.4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1161\/STROKEAHA.120.032809","article-title":"Predictors of Outcomes in Patients With Mild Ischemic Stroke Symptoms: MaRISS","volume":"52","author":"Romano","year":"2021","journal-title":"Stroke"},{"key":"2026090805001769000_16.9.e119290.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00124-7"},{"key":"2026090805001769000_16.9.e119290.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411587"},{"key":"2026090805001769000_16.9.e119290.7","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5070","article-title":"Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review)","volume":"49","author":"Zhao","year":"2022","journal-title":"Int J Mol Med"},{"key":"2026090805001769000_16.9.e119290.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"2026090805001769000_16.9.e119290.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15692-4"},{"key":"2026090805001769000_16.9.e119290.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60491-6"},{"key":"2026090805001769000_16.9.e119290.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30258-0"},{"key":"2026090805001769000_16.9.e119290.12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0140-6736(25)00194-1","article-title":"Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial","volume":"405","author":"Hill","year":"2025","journal-title":"Lancet"},{"key":"2026090805001769000_16.9.e119290.13","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000025518.34157.51"},{"key":"2026090805001769000_16.9.e119290.14","first-page":"796","article-title":"Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats","volume":"24","author":"Chang","year":"2003","journal-title":"Acta Pharmacol Sin"},{"key":"2026090805001769000_16.9.e119290.15","first-page":"2615","article-title":"Protective effects of dl-3n-butylphthalide against diffuse brain injury","volume":"8","author":"Zhao","year":"2013","journal-title":"Neural Regen Res"},{"key":"2026090805001769000_16.9.e119290.16","first-page":"411","article-title":"The protective effect of butylphthalide against mitochondrial injury during cerebral ischemia","volume":"35","author":"Xiong","year":"2000","journal-title":"Yaoxue Xuebao"},{"key":"2026090805001769000_16.9.e119290.17","first-page":"433","article-title":"Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats","volume":"21","author":"Xu","year":"2000","journal-title":"Acta Pharmacol Sin"},{"key":"2026090805001769000_16.9.e119290.18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaneurol.2023.1871","article-title":"Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial","volume":"80","author":"Wang","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026090805001769000_16.9.e119290.19","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3760\/cma.j.issn.0366-6999.20123240","article-title":"Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: a randomized, double-blind trial","volume":"126","author":"Cui","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"2026090805001769000_16.9.e119290.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"2026090805001769000_16.9.e119290.21","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.572883"},{"key":"2026090805001769000_16.9.e119290.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.7827"},{"key":"2026090805001769000_16.9.e119290.23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamaneurol.2020.4557","article-title":"Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone","volume":"78","author":"Seners","year":"2021","journal-title":"JAMA Neurol"},{"key":"2026090805001769000_16.9.e119290.24","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.001584"},{"key":"2026090805001769000_16.9.e119290.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02600-9"},{"key":"2026090805001769000_16.9.e119290.26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke","volume":"8","author":"Alamowitch","year":"2023","journal-title":"European Stroke Journal"},{"key":"2026090805001769000_16.9.e119290.27","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01391-3"},{"key":"2026090805001769000_16.9.e119290.28","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209903","article-title":"Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"103","author":"Palaiodimou","year":"2024","journal-title":"Neurology"},{"key":"2026090805001769000_16.9.e119290.29","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"The Lancet"},{"key":"2026090805001769000_16.9.e119290.30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036275","article-title":"Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study Cohort","volume":"13","author":"Ornello","year":"2024","journal-title":"JAHA"},{"key":"2026090805001769000_16.9.e119290.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00519-1"},{"key":"2026090805001769000_16.9.e119290.32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1142\/S0192415X19500265","article-title":"A Systematic Review of Neuroprotective Efficacy and Safety of DL-3-N-Butylphthalide in Ischemic Stroke","volume":"47","author":"Xu","year":"2019","journal-title":"Am J Chin Med"},{"key":"2026090805001769000_16.9.e119290.33","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.720664","article-title":"Efficacy and Safety of Adherence to dl-3-n-Butylphthalide Treatment in Patients With Non-disabling Minor Stroke and TIA-Analysis From a Nationwide, Multicenter Registry","volume":"12","author":"Tan","year":"2021","journal-title":"Front Neurol"},{"key":"2026090805001769000_16.9.e119290.34","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/S0140-6736(24)00981-4","article-title":"Advances and challenges in the acute treatment of minor ischaemic stroke","volume":"403","author":"Sacco","year":"2024","journal-title":"Lancet"},{"key":"2026090805001769000_16.9.e119290.35","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.796046","article-title":"Large Vessel Occlusion in Patients With Minor Ischemic Stroke in a Population-Based Study. The Dijon Stroke Registry","volume":"12","author":"Duloquin","year":"2021","journal-title":"Front Neurol"},{"key":"2026090805001769000_16.9.e119290.36","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.098517"},{"key":"2026090805001769000_16.9.e119290.37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00394","article-title":"N-Butylphthalide Alleviates Blood-Brain Barrier Impairment in Rats Exposed to Carbon Monoxide","volume":"7","author":"Bi","year":"2016","journal-title":"Front Pharmacol"},{"key":"2026090805001769000_16.9.e119290.38","doi-asserted-by":"crossref","first-page":"112420","DOI":"10.1016\/j.yexcr.2020.112420","article-title":"Dl-3-n-butylphthalide promotes neurite outgrowth of primary cortical neurons by Sonic Hedgehog signaling via upregulating Gap43","volume":"398","author":"Zhang","year":"2021","journal-title":"Exp Cell Res"},{"key":"2026090805001769000_16.9.e119290.39","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.18632\/aging.202338","article-title":"Dl-3-n-butylphthalide inhibits neuroinflammation by stimulating foxp3 and Ki-67 in an ischemic stroke model","volume":"13","author":"Liu","year":"2021","journal-title":"Aging"},{"key":"2026090805001769000_16.9.e119290.40","doi-asserted-by":"crossref","DOI":"10.1002\/cns.70698","article-title":"Dl\u20103\u2010n\u2010Butylphthalide Promotes Cortical Angiogenesis via Akt\/GSK\u20103\u03b2 Signaling in Ischemic Stroke Mice","volume":"31","author":"Zhang","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"2026090805001769000_16.9.e119290.41","doi-asserted-by":"crossref","DOI":"10.1002\/cns.70682","article-title":"DL-3-n-Butylphthalide Protects Mitochondria Against Ischemia\/Hypoxia Damage via Suppressing GCN5L1-Mediated Drp1 Acetylation in Neurons and Mouse Brains","volume":"31","author":"Zhang","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"2026090805001769000_16.9.e119290.42","doi-asserted-by":"crossref","first-page":"109237","DOI":"10.1016\/j.bioorg.2025.109237","article-title":"Novel 3-n-butylphthalide derivatives as potent multi-functional anti-IS agents with BBB protective function","volume":"167","author":"Shao","year":"2025","journal-title":"Bioorg Chem"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-119290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:58:04Z","timestamp":1788962284000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-119290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-119290"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-119290","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}